

Supplementary Material

Kabachnik–Fields reactions with stable nitroxide free radicals

Mostafa Isbera,^a Balázs Bognár,^a Cecília Sár,^a József Jekő,^b Tamás Kálai^{a,c,*}

^a*Institute of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs,
Szigeti st. 12, H-7624 Pécs, Hungary*



^b*Department of Chemistry, University of Nyíregyháza, Sóstói st. 31/B, H-4440 Nyíregyháza,
Hungary*



^c*János Szentágothai Research Center, University of Pécs, Ifjúság 20, H-7624 Pécs, Hungary*
Email: tamas.kalai@aok.pte.hu



Table of Contents



| | |
|---|-----|
| S1. ¹ H NMR and ¹³ C NMR of compound 3 | S2 |
| S2. ¹ H NMR and ¹³ C NMR of compound 4 | S3 |
| S3. ¹ H NMR and ¹³ C NMR of compound 5 | S4 |
| S4. ¹ H NMR and ¹³ C NMR of compound 6 | S5 |
| S5. ¹ H NMR and ¹³ C NMR of compound 7 | S6 |
| S6. ¹ H NMR and ¹³ C NMR of compound 9 | S7 |
| S7. ¹ H NMR and ¹³ C NMR of compound 10 | S8 |
| S8. ¹ H NMR and ¹³ C NMR of compound 13 | S9 |
| S9. ¹ H NMR and ¹³ C NMR of compound 15 | S10 |
| S10. ¹ H NMR and ¹³ C NMR of compound 16 | S11 |
| S11. ¹ H NMR and ¹³ C NMR of compound 17 | S12 |
| S12. ¹ H NMR and ¹³ C NMR of compound 18 | S13 |
| S13. EPR of compound 18 | S14 |



(Diethyl ((phenylamino)(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)phosphonate-1-yl)oxydanyl (**3**):







(Diethyl ((phenylamino)(4-bromo-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)phosphonate-1-yl)oxydanyl (**4**)



(Diethyl ((phenylamino)(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)phosphonate-1-yl)oxydanyl (**5**)

(Diethyl ((benzylamino)(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)phosphonate-1-yl)oxydanyl (**6**)



(Diethyl (6,6,8,8-tetramethyl-3,4,5,6,7,8-hexahydro-2H-pyrrolo[3,4-f][1,4]thiazepin-5-yl)phosphonate-7yl)oxydanyl (**7**)

(Diethyl (4-(benzylamino)-2,2,6,6-tetramethylpiperidin-4-yl)phosphonate-1-yl)oxydanyl (**9**)



(Diethyl (4-amino-2,2,6,6-tetramethylpiperidin-4-yl)phosphonate-1-yl)oxydanyl (**10**)



(Diethyl (((2,2,6,6-tetramethylpiperidin-4-yl)amino)(phenyl)methyl)phosphonate-1-yl)oxydanyl (**13**)



(Diethyl (((2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)amino)(phenyl)methyl)phosphonate-1-yl)oxydanyl (**15**)



(Diethyl (((2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-3-yl)methyl)amino)(2-iodophenyl)methyl)phospho-nate-1-yl)oxydanyl (**16**):



(Diethyl (((2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)amino)(4-methoxyphenyl)methyl)phosphonate-1yl)oxydanyl (**17**):

(Diethyl ((2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-3-yl)((2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-3-yl)methyl)amino)methyl)phosphonate)-1,1-diyl)dioxydanyl (**18**)

(Diethyl ((2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-3-yl)(((2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-3-yl)methyl)amino)methyl)phosphonate)-1,1-diyl)dioxydanyl (**18**)

EPR of biradical **18** 1×10^{-4} M in CHCl_3

